PLATINANING KOMPLEKS BIRIKMALARI VA AHAMYATLI TOMONLARI
Основное содержимое статьи
Аннотация
Platina -kumushdek,oq yoki kumushsimon,qiyin suyuqlanadigan, qiyin uchuvchan elimentdir.Ushbu maqolamda platinaning kompleks birikmalari va ahamyatli tomonlari hamda inson hayotidagi o'rni haqida aytib o'tiladi.Platina asosidagi dorilar sisplatin, karboplatinva oksaliplatin saratonni kimyoterapevtik yo'q qilish uchun keng qo'llaniladi. Platinaning mana shunday muhim birikmalari haqida so'z boradi.
Информация о статье
Библиографические ссылки
Kimyo bo‘yicha qo‘llanma/ Redcol:Nikolskiy.B.P va boshqalar.2-nashr, ex.M.-L.:Kimyo 2010. T.1072b.
Lidin R.A. va boshqalar.Noorganik moddalarning kimyoviy xossalari:Darslik.universitetlar uchun qo‘llanma.-3-nashr,rev.-M.:Kimyo,2000. 480b
Peyrone M.Ammiakning platina xloriga ta’siri haqida.Kimyo va farmatsiya 2000; 51: 1-29
Wellstein A,Giaccone G,Atkins MB,Sausville EA. Cyotoxic agents. In, Brunton LL,Hilal-Dandan R,Knollman BC,eds.Goodman& Gilman’s the pharmacological basis of therapeutics.13 th ed. NewYork:McGraw- Hill, 2018, pp.1167-201.
O‘zbekiston milliy ensiklopediyasi. Birinchi jild. Toshkent, 2005- yil.
Graham J,Mushin M,Kirkpatrick P(January 2004). “Oxaliplatin”.Nature Reviews. Drug Discovery.3(1):11-12.doi:10.1038/nrd1287.
Химическая энциклопедия/Редкол:Кнунянц И.Л.и др..-М.:Советская энциклопедия,1992.-Т.З. – 639С.
Ripan R., Ceteanu I.Noorganik kimyo.Metallar kimyosi.1999-yil.T.
Harper, Douglas.”platinum”.Online Etymology Dictionary.
Almeida LO, Neto MPC, Sousa LO, et al. SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation. Oncotarget. 2017; 8:26802‐26818. [PMC free article] [PubMed] [Google Scholar] https:pubmed. Ncbi.nih.gov.
ReynoldsC. P.MaurerB. J.2005Platinum Complexes with Bioactive Nitroxyl Radicals: Synthesis and Antitumor PropertiesMethods Mol. Med.,110173183
Shimoyama T, Kato K, Miyaji‐Yamaguchi M, et al. Synergistic action of MLL, a TRX protein with template activating factor‐I, a histone chaperone. FEBS Lett. 2005; 579:757‐762.
Agarwal A, MacKenzie RJ, Pippa R, et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res. 2014;20:2092‐2103
Richard NP, Pippa R, Cleary MM, et al. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T‐cell acute lymphoblastic leukemia. Oncotarget. 2016;7:84214‐84227